DexCom Shares Tumble Nearly 36% After Company Cuts Sales Forecast

Dow Jones07-26

'While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,' CEO says.

DexCom Inc., a maker of monitoring devices for diabetes patients, cut its full-year sales outlook on Thursday - a move that surprised some analysts and investors and sent its stock tumbling after hours - as the company deals with a shortfall in new patients and weaker trends abroad.

Shares of DexCom were down 36% after hours on Thursday, after holding steady through much of the year.

DexCom - which makes glucose-monitoring systems, some of which can connect to smartphones and other wearable devices like the Apple Watch - said it expected full-year sales of around $4 billion to $4.05 billion. That's down from an outlook in April for $4.2 billion to $4.35 billion.

"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards," Chief Executive Kevin Sayer said in a statement.

During the company's earnings call, executives said the company was short "a large number of new patients" relative to where they thought they would be. They also cited snags it hit in its U.S. salesforce expansion, issues with rebate eligibility and a softer-than-expected performance internationally.

The forecast arrives as the company tries to capitalize on the rise of real-time monitoring technology. But DexCom's sales during the second quarter missed expectations, while its adjusted per-share profits beat.

Shares of DexCom are down 13% so far this year.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

1

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2454933371?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-07-26 06:59","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2454933371","market":"nz","top_or_hot":-1,"title":"DexCom Shares Tumble Nearly 36% After Company Cuts Sales Forecast","media":"Dow Jones","content":"<html><head></head><body><p>&#39;While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,&#39; CEO says.</p><p>DexCom Inc., a maker of monitoring devices for diabetes patients, cut its full-year sales outlook on Thursday - a move that surprised some analysts and investors and sent its stock tumbling after hours - as the company deals with a shortfall in new patients and weaker trends abroad.</p><p>Shares of  <a href=\"https://laohu8.com/S/DXCM\">DexCom</a>  were down 36% after hours on Thursday, after holding steady through much of the year.</p><p></p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/929a1af335c59215daf34f6f83d4b11d\" tg-width=\"407\" tg-height=\"387\"/></p><p>DexCom - which makes glucose-monitoring systems, some of which can connect to smartphones and other wearable devices like the Apple Watch - said it expected full-year sales of around $4 billion to $4.05 billion. That&#39;s down from an outlook in April for $4.2 billion to $4.35 billion.</p><p>&#34;While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,&#34; Chief Executive Kevin Sayer said in a statement.</p><p>During the company&#39;s earnings call, executives said the company was short &#34;a large number of new patients&#34; relative to where they thought they would be. They also cited snags it hit in its U.S. salesforce expansion, issues with rebate eligibility and a softer-than-expected performance internationally.</p><p>The forecast arrives as the company tries to capitalize on the rise of real-time monitoring technology. But DexCom&#39;s sales during the second quarter missed expectations, while its adjusted per-share profits beat.</p><p>Shares of DexCom are down 13% so far this year.</p><p></p></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>DexCom Shares Tumble Nearly 36% After Company Cuts Sales Forecast</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nDexCom Shares Tumble Nearly 36% After Company Cuts Sales Forecast\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-07-26 06:59 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://dowjonesnews.com/newdjn/logon.aspx?AL=N><strong>Dow Jones</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>'While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,' CEO says.DexCom Inc., a maker of monitoring devices for diabetes ...</p>\n\n<a href=\"https://dowjonesnews.com/newdjn/logon.aspx?AL=N\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":null,"symbol_name":null,"start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2454933371","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2454933371","pubTimestamp":1721948364,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"'While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,' CEO says. DexCom Inc., a maker of monitoring devices for diabetes patients, cut its full-year sales outlook on Thursday - a move that surprised some analysts and investors and sent its stock tumbling after hours - as the company deals with a shortfall in new patients and weaker trends abroad.Shares of DexCom  were down 39.7% after hours on Thursday, after holding steady through much of the year.DexCom - which makes glucose-monitoring systems, some of which can connect to smartphones and other wearable devices like the Apple Watch - said it expected full-year sales of around $4 billion to $4.05 billion. That's down from an outlook in April for $4.2 billion to $4.35 billion.During the company's earnings call, executives said the company was short \"a large number of new patients\" relative to where they thought they would be. They also cited snags it hit in its U.","collect":0,"end_time":0,"defaultTopTitle":"","property":["earning"],"viewcount":null,"language":"en","relate_stocks":{},"translate_title":"DexCom下调销售预期后股价暴跌近36%","themeId":"c0d77e622a6742cf8335299f8317b4b4","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{},"content_text":"'While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,' CEO says.DexCom Inc., a maker of monitoring devices for diabetes patients, cut its full-year sales outlook on Thursday - a move that surprised some analysts and investors and sent its stock tumbling after hours - as the company deals with a shortfall in new patients and weaker trends abroad.Shares of  DexCom  were down 36% after hours on Thursday, after holding steady through much of the year.DexCom - which makes glucose-monitoring systems, some of which can connect to smartphones and other wearable devices like the Apple Watch - said it expected full-year sales of around $4 billion to $4.05 billion. That's down from an outlook in April for $4.2 billion to $4.35 billion.\"While Dexcom advanced several key strategic initiatives in the second quarter, our execution did not meet our high standards,\" Chief Executive Kevin Sayer said in a statement.During the company's earnings call, executives said the company was short \"a large number of new patients\" relative to where they thought they would be. They also cited snags it hit in its U.S. salesforce expansion, issues with rebate eligibility and a softer-than-expected performance internationally.The forecast arrives as the company tries to capitalize on the rise of real-time monitoring technology. But DexCom's sales during the second quarter missed expectations, while its adjusted per-share profits beat.Shares of DexCom are down 13% so far this year.","kind":"highlight","is_publish_news":true,"is_publish_highlight":true,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"dataReport,movement","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":1,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2454933371"}